Journal of Obesity & Metabolic Syndrome

Table. 5. Table 5

Adverse events (AEs) of phentermine/topiramate

Authors	Number of subjects	Duration (months)	Common AEs	Serious AEs	Psychiatric/cognitive AEs
Allison et al. (2012)³⁴ (EQUIP)	1,267	13	*Paresthesia	Cholelithiasis (1)	Insomnia (40, high dose)
			*Dry mouth	Myelogenous leukemia (1)	Depression (24, high dose)
			*Constipation		Irritability (23, high dose)
			*Dysgeusia		Anxiety (19, high dose)
			*Nasopharyngitis		Disturbance in attention (18, high dose)
			*Blurred vision (low dose, P=0.05)		Jittery (7, high dose)
			*Alopecia
			*Hypoesthesia
			*Dry eye
			*Oral paresthesia
			*Dry skin
			*Anorexia
			*Decreased serum bicarbonate
			*Amenorrhea
			*Aphasia
			*Back injury
			*Decreased serum potassium
			*Parosmia
Gadde et al. (2011)³⁵ (CONQUER)	2,487	13	^†Dry mouth		Anxiety (41, high dose)
			^†Paresthesia		Irritability (34, high dose)
			^†Constipation		Disturbance in attention (35, high dose)
			^†Dysgeusia
			^†Insomnia
			^†Dizziness
			^†Back pain
			^†Nausea
			^†Blurred vision
Garvey et al. (2012)⁴ (SEQUEL)	676	25 (extension of CONQUER)	^‡Paraesthesia
Garvey et al. (2012)⁴ (SEQUEL)	676	25 (extension of CONQUER)	^‡Nausea

Number in () means number of cases with the adverse events.*

Occured at a rate of ≥1% in any treatment group and more frequently than in placebo group (P<0.05)

†

Occured at a rate of ≥5% in any treatment group and more frequently than in placebo group (P<0.05)

‡

In the second year, paresthesia occurred more in high dose group and nausea occurred more in low dose group than in placebo group (P<0.05 by Fisher’s exact test)

Korean J Obes 2015;24:17~27 https://doi.org/10.7570/kjo.2015.24.1.17